Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance (AMR)
The Declaration on Combating Antimicrobial Resistance (AMR) represents a major milestone in the global response to the rising threat of drug resistance with commercial drug and diagnostic developers for the first time agreeing on a common set of principles.
By bringing together a wide range of companies, the Declaration provides a valuable roadmap to guide further collaborative efforts between industry, governments and NGOs in the global fightback against AMR.
In January 2016, leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, have come together to call on governments and industry to work together in taking collective action against drug-resistant infections, with a joint Declaration launched at the World Economic Forum (WEF) in Davos, Switzerland (to read the press release click here). The Declaration sets out a common set of principles for global action to support antibiotic conservation and the development of new drugs, diagnostics and vaccines. The declaration is composed of two parts:
1) A call to action for governments
In the Declaration, signatories call on governments to work with them to develop new and alternative market structures that provide more dependable and sustainable market models for antibiotics. These mechanisms are needed to provide appropriate incentives (coupled with safeguards to support antibiotic conservation) for companies to invest in R&D to overcome the formidable technical and scientific challenges of antibiotic discovery and development. These include mechanisms to ensure that, where appropriate, the pricing of antibiotics more adequately reflects the benefits they bring; and novel payment models that reduce the link between the profitability of an antibiotic and the volume sold.
2) A series of commitments from the signatory companies
The Declaration also sets out commitments to further action on drug resistance by its signatories, across three broad areas. They commit to:
The Declaration remains a living document. When published in January 2016, the Declaration had been signed by 85 companies and nine industry associations from across the global pharmaceutical, diagnostics and biotechnology industries. As of 1st April 2016, a total of 98 companies and 11 industry associations in 21 countries have added their signatures to it.
The Industry Declaration
was launched on 21st January 2016 in Davos
The Industry Declaration
has been signed by 98 companies and 11 industry associations in 21 countries
10 million people
may die every year from bacterial infection in 2050